Oxaliplatin
Mostrando 1-12 de 17 artigos, teses e dissertações.
-
1. Hepatic changes after treatment with oxaliplatin
Radiol Bras. Publicado em: 24/10/2019
-
2. Effect of FOLFOX6 chemotherapy on serum VEGF expression in advanced colorectal cancer patients
RESUMO OBJETIVO: Explorar o efeito da quimioterapia Folfox6 na expressão do fator de crescimento endotelial vascular sérico (VEGF) em pacientes com câncer colorretal avançado. MÉTODOS: Uma análise retrospectiva de 81 pacientes com câncer colorretal avançado que visitaram nosso hospital de março de 2014 a fevereiro de 2016 foi realizada. Todos os p
Rev. Assoc. Med. Bras.. Publicado em: 2019-02
-
3. Relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer in China
OBJECTIVES: To study the relationship between the Asp1104His polymorphism of the nucleotide excision repair gene ERCC5 and treatment sensitivity to oxaliplatin in patients with advanced colorectal cancer (CRC) in China. METHODS: A group of 226 patients in the Department of Gastrointestinal Oncology at Zhejiang Xiaoshan Hospital from July 2011∼December 20
Clinics. Publicado em: 03/12/2018
-
4. Influence of PLGA and PLGA-PEG on the dissolution profile of oxaliplatin
Abstract Oxaliplatin was inserted into polymeric matrices aiming to study the interaction of this drug with these polymers and its capability to diffuse to the environment. Tested polymers were: (1) polyethylene glycol (PEG), (2) poly(lactic-co-glycolic acid) (PLGA), and (3) a copolymer of them (PLGA-PEG). The latter two were synthesized by us using polycond
Polímeros. Publicado em: 07/06/2016
-
5. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer
Cisplatin resistance remains one of the major obstacles when treating epithelial ovarian cancer. Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of transcription 3 (STAT3) is associated with cisplatin resistance, we investigated whether overcoming cisplatin res
Braz J Med Biol Res. Publicado em: 13/08/2013
-
6. Efeito protetor da amifostina na neuropatia sensitiva perifÃrica experimental induzida por oxaliplatina. / Protective effect of amifostine upon experimental oxaliplatin-induced sensory peripheral neuropathy.
Oxaliplatina (OXL) Ã um agente platÃnico de 3Â geraÃÃo com potente atividade citotÃxica em diversos cÃnceres. Tem como toxicidade limitante uma neuropatia sensitiva perifÃrica (NSP) de inÃcio agudo, tornando-se crÃnica com doses cumulativas. Amifostina (AMF) Ã um agente antioxidante de largo espectro, que vem sendo atualmente estudado na citoprote
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 11/03/2011
-
7. Irinotecan and oxaliplain : an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer
Colorectal cancer is one of the most frequent malignancies in humans and an important cause of cancer death. Metastatic colorectal cancer remains incurable with available systemic therapeutic options. The most active cytotoxic drug against this malignancy, the antimetabolite 5-fluorouracil, was developed more than forty years ago, and as a single agent produ
Publicado em: 2010
-
8. Desenvolvimento de modelo experimental de neuropatia sensitiva perifÃrica induzida pelo agente antineoplÃsico oxaliplatina em camundongos. / Development of experimental model of peripheral sensitive neuropathy prompted by the oxaliplatin in mice.
Oxaliplatina (OXL) Ã a 3Â geraÃÃo de agentes platinos com amplo espectro de atividade antitumoral. Exibe potente atividade citotÃxica, incluindo cÃncer colorretal, ovariano e pulmonar. Dentre os efeitos tÃxicos estÃo: laringoespasmo, nÃuseas, vÃmitos, fadiga e neuropatia perifÃrica, foco desse trabalho. Essa pesquisa objetivou desenvolver um model
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 18/12/2009
-
9. Irinotecan and oxaliplatin: an overview of the novel chemotherapeutic options for the treatment of advanced colorectal cancer
Colorectal cancer is one of the most frequent malignancies in humans and an important cause of cancer death. Metastatic colorectal cancer remains incurable with available systemic therapeutic options. The most active cytotoxic drug against this malignancy, the antimetabolite 5-fluorouracil, was developed more than forty years ago, and as a single agent produ
Brazilian Journal of Medical and Biological Research. Publicado em: 2001-09
-
10. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibilit
Nature Publishing Group.
-
11. Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells
Nature Publishing Group.
-
12. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines
Blackwell Publishing Ltd.